---
{"dg-publish":true,"permalink":"/research/tags/urolithin-a/","updated":"2025-01-30T16:37:06-05:00"}
---

# Tagged Content
<div><table class="dataview table-view-table"><thead class="table-view-thead"><tr class="table-view-tr-header"><th class="table-view-th"><span>Takeaways</span><span class="dataview small-text">5</span></th><th class="table-view-th"><span></span></th></tr></thead><tbody class="table-view-tbody"><tr><td><span><a data-tooltip-position="top" aria-label="Research/Takeaways/2025-01-28 20-21-29.md" data-href="Research/Takeaways/2025-01-28 20-21-29.md" href="Research/Takeaways/2025-01-28 20-21-29.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 20-21-29</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose greater than 0.2 mg/kg/day may relieve neuropathic pain</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Takeaways/2025-01-28 20-20-50.md" data-href="Research/Takeaways/2025-01-28 20-20-50.md" href="Research/Takeaways/2025-01-28 20-20-50.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 20-20-50</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose of 20.3 mg/kg/day may reduce <a data-href="Sinovitis" href="Sinovitis" class="internal-link" target="_blank" rel="noopener nofollow">Sinovitis</a></span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Takeaways/2025-01-28 20-20-37.md" data-href="Research/Takeaways/2025-01-28 20-20-37.md" href="Research/Takeaways/2025-01-28 20-20-37.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 20-20-37</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose of at least 20.3 mg/kg/day may reduce the pain from <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a></span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Takeaways/2025-01-28 20-19-26.md" data-href="Research/Takeaways/2025-01-28 20-19-26.md" href="Research/Takeaways/2025-01-28 20-19-26.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 20-19-26</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose of at least 20.3 mg/kg/day may reduce the progression of <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a></span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Takeaways/2025-01-28 20-12-29.md" data-href="Research/Takeaways/2025-01-28 20-12-29.md" href="Research/Takeaways/2025-01-28 20-12-29.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 20-12-29</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose of at least 4 mg/kg/day may reduce the progression of <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> degeneration</span></td></tr></tbody></table></div><div><table class="dataview table-view-table"><thead class="table-view-thead"><tr class="table-view-tr-header"><th class="table-view-th"><span>Insights</span><span class="dataview small-text">31</span></th><th class="table-view-th"><span></span></th></tr></thead><tbody class="table-view-tbody"><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-28-05.md" data-href="Research/Insights/2025-01-30 15-28-05.md" href="Research/Insights/2025-01-30 15-28-05.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-28-05</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> reduces the number of TUNEL-positive cells in the <a data-href="Nucleus Pulposus" href="Nucleus Pulposus" class="internal-link" target="_blank" rel="noopener nofollow">Nucleus Pulposus</a> at a dose of 25 mg/kg/day when taken for 4 weeks after an <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> puncture at 8 weeks of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-37-02.md" data-href="Research/Insights/2025-01-30 15-37-02.md" href="Research/Insights/2025-01-30 15-37-02.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-37-02</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> slows the reduction in <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> histological score at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-35-56.md" data-href="Research/Insights/2025-01-30 15-35-56.md" href="Research/Insights/2025-01-30 15-35-56.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-35-56</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> slows the progressive loss of <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> height at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 12 weeks of age compared to rats not fed Urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-34-35.md" data-href="Research/Insights/2025-01-30 15-34-35.md" href="Research/Insights/2025-01-30 15-34-35.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-34-35</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> slows the progression of <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> degeneration at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-34-20.md" data-href="Research/Insights/2025-01-30 15-34-20.md" href="Research/Insights/2025-01-30 15-34-20.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-34-20</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> slows the progression of <a data-href="Pfirrmann Grade" href="Pfirrmann Grade" class="internal-link" target="_blank" rel="noopener nofollow">Pfirrmann Grade</a> at a dose of 25 mg/kg/day when taken for 4 weeks after an <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> puncture at 12 weeks of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-33-56.md" data-href="Research/Insights/2025-01-30 15-33-56.md" href="Research/Insights/2025-01-30 15-33-56.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-33-56</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> slows the progression of <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> degeneration at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 12 weeks of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-32-27.md" data-href="Research/Insights/2025-01-30 15-32-27.md" href="Research/Insights/2025-01-30 15-32-27.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-32-27</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> slows the progression in <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> <a data-href="Pfirrmann Grade" href="Pfirrmann Grade" class="internal-link" target="_blank" rel="noopener nofollow">Pfirrmann Grade</a> at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-31-32.md" data-href="Research/Insights/2025-01-30 15-31-32.md" href="Research/Insights/2025-01-30 15-31-32.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-31-32</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> slows the increase in histologic score at a dose of 25 mg/kg/day when taken for 4 weeks after an <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> puncture at 12 weeks of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-30-53.md" data-href="Research/Insights/2025-01-30 15-30-53.md" href="Research/Insights/2025-01-30 15-30-53.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-30-53</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> reduces the serum levels of <a data-href="Matrix Metalloproteinase-3 (MMP3)" href="Matrix Metalloproteinase-3 (MMP3)" class="internal-link" target="_blank" rel="noopener nofollow">Matrix Metalloproteinase-3 (MMP3)</a> in mice at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-26-59.md" data-href="Research/Insights/2025-01-30 15-26-59.md" href="Research/Insights/2025-01-30 15-26-59.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-26-59</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> reduces the knee OARSI score of mice at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-25-18.md" data-href="Research/Insights/2025-01-30 15-25-18.md" href="Research/Insights/2025-01-30 15-25-18.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-25-18</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> reduces the <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> histological score at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 8 weeks of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-24-17.md" data-href="Research/Insights/2025-01-30 15-24-17.md" href="Research/Insights/2025-01-30 15-24-17.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-24-17</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> reduces the <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> <a data-href="Pfirrmann Grade" href="Pfirrmann Grade" class="internal-link" target="_blank" rel="noopener nofollow">Pfirrmann Grade</a> at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 8 weeks of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-23-29.md" data-href="Research/Insights/2025-01-30 15-23-29.md" href="Research/Insights/2025-01-30 15-23-29.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-23-29</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> reduces markers of the progression of knee <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-23-01.md" data-href="Research/Insights/2025-01-30 15-23-01.md" href="Research/Insights/2025-01-30 15-23-01.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-23-01</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> may reduce the pain response to a 4g Von Frey filament at a dose of either 250 mg/kg/day or 50 mg/kg/day compared to control when taken for 8 weeks after the induction of experimental <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-21-19.md" data-href="Research/Insights/2025-01-30 15-21-19.md" href="Research/Insights/2025-01-30 15-21-19.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-21-19</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> may reduce the pain response to a 4g Von Frey filament at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 4 weeks after the induction of experimental <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-20-59.md" data-href="Research/Insights/2025-01-30 15-20-59.md" href="Research/Insights/2025-01-30 15-20-59.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-20-59</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> may reduce the pain from knee <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> in mice at a dose of either 250 mg/kg/day or 50 mg/kg/day when taken for 8 weeks after the induction of experimental <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-18-57.md" data-href="Research/Insights/2025-01-30 15-18-57.md" href="Research/Insights/2025-01-30 15-18-57.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-18-57</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> may reduce knee <a data-href="Sinovitis" href="Sinovitis" class="internal-link" target="_blank" rel="noopener nofollow">Sinovitis</a> at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-18-26.md" data-href="Research/Insights/2025-01-30 15-18-26.md" href="Research/Insights/2025-01-30 15-18-26.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-18-26</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> increases the cell number in non-calcified knee <a data-href="Cartilage" href="Cartilage" class="internal-link" target="_blank" rel="noopener nofollow">Cartilage</a> of mice at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-17-08.md" data-href="Research/Insights/2025-01-30 15-17-08.md" href="Research/Insights/2025-01-30 15-17-08.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-17-08</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> increases the <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> disc height index at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-15-20.md" data-href="Research/Insights/2025-01-30 15-15-20.md" href="Research/Insights/2025-01-30 15-15-20.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-15-20</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> increases the <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> <a data-href="Collagen Type II" href="Collagen Type II" class="internal-link" target="_blank" rel="noopener nofollow">Collagen Type II</a> fluorescence at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-14-32.md" data-href="Research/Insights/2025-01-30 15-14-32.md" href="Research/Insights/2025-01-30 15-14-32.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-14-32</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> increases the <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> <a data-href="Aggrecan" href="Aggrecan" class="internal-link" target="_blank" rel="noopener nofollow">Aggrecan</a> fluorescence at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 4-6 months of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15-11-44.md" data-href="Research/Insights/2025-01-30 15-11-44.md" href="Research/Insights/2025-01-30 15-11-44.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15-11-44</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> can reduce the pain response to a 1g Von Frey filament at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 15 28 41.md" data-href="Research/Insights/2025-01-30 15 28 41.md" href="Research/Insights/2025-01-30 15 28 41.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 15 28 41</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> reduces the progression of <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> degeneration at a dose of 25 mg/kg/day when taken for 4 weeks after an IVD puncture at 8 weeks of age compared to rats not fed urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-30 14-16-21.md" data-href="Research/Insights/2025-01-30 14-16-21.md" href="Research/Insights/2025-01-30 14-16-21.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-30 14-16-21</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>Taking <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> with high-protein yogurt (17 grams) in the morning while fasting does not impact the bioavailability of urolithin A at doses of 500 mg or 1000 mg</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-29 10-52-06.md" data-href="Research/Insights/2025-01-29 10-52-06.md" href="Research/Insights/2025-01-29 10-52-06.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-29 10-52-06</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>Daily intraperitoneal injections of 2.5 mg/kg <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> in mice reduce the pain-related behavioral deficits from chronic <a data-href="Sciatic Nerve" href="Sciatic Nerve" class="internal-link" target="_blank" rel="noopener nofollow">Sciatic Nerve</a> constriction compared to mice not administered urolithin A when injections begin immediately after constriction surgery</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-29 10-46-32.md" data-href="Research/Insights/2025-01-29 10-46-32.md" href="Research/Insights/2025-01-29 10-46-32.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-29 10-46-32</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>Daily intraperitoneal injections of 2.5 mg/kg <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> in mice reduce pain from chronic <a data-href="Sciatic Nerve" href="Sciatic Nerve" class="internal-link" target="_blank" rel="noopener nofollow">Sciatic Nerve</a> constriction compared to mice not administered urolithin A</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-29 10-43-15.md" data-href="Research/Insights/2025-01-29 10-43-15.md" href="Research/Insights/2025-01-29 10-43-15.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-29 10-43-15</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose of 250 mg/kg/day is likely better than a dose of 50 mg/kg/day at reducing the pain from knee <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> in mice when taken for 8 weeks after the induction of experimental arthritis at 4 months of age</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-29 10-42-32.md" data-href="Research/Insights/2025-01-29 10-42-32.md" href="Research/Insights/2025-01-29 10-42-32.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-29 10-42-32</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose of 250 mg/kg/day in a mouse equates to 20.3 mg/kg/day in a human</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-29 10-41-13.md" data-href="Research/Insights/2025-01-29 10-41-13.md" href="Research/Insights/2025-01-29 10-41-13.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-29 10-41-13</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose of 25 mg/kg/day in a rat equates to 4 mg/kg/day in a human</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-29 10-40-59.md" data-href="Research/Insights/2025-01-29 10-40-59.md" href="Research/Insights/2025-01-29 10-40-59.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-29 10-40-59</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose greater than 0.2 mg/kg may relieve pain from constriction of the <a data-href="Sciatic Nerve" href="Sciatic Nerve" class="internal-link" target="_blank" rel="noopener nofollow">Sciatic Nerve</a></span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Insights/2025-01-29 10-39-17.md" data-href="Research/Insights/2025-01-29 10-39-17.md" href="Research/Insights/2025-01-29 10-39-17.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-29 10-39-17</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>A <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> dose of 2.5 mg/kg/day in a mouse is equivalent to 0.2 mg/kg/day in a human</span></td></tr></tbody></table></div><div><table class="dataview table-view-table"><thead class="table-view-thead"><tr class="table-view-tr-header"><th class="table-view-th"><span>Assumptions</span><span class="dataview small-text">6</span></th><th class="table-view-th"><span></span></th></tr></thead><tbody class="table-view-tbody"><tr><td><span><a data-tooltip-position="top" aria-label="Research/Assumptions/2025-01-28 21-36-55.md" data-href="Research/Assumptions/2025-01-28 21-36-55.md" href="Research/Assumptions/2025-01-28 21-36-55.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 21-36-55</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>The pain from all types of <a data-href="Neuropathy" href="Neuropathy" class="internal-link" target="_blank" rel="noopener nofollow">Neuropathy</a> are equally sensitive to treatment by <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a></span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Assumptions/2025-01-28 21-35-03.md" data-href="Research/Assumptions/2025-01-28 21-35-03.md" href="Research/Assumptions/2025-01-28 21-35-03.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 21-35-03</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>The progression of all types of <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> is equally sensitive to treatment by <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a></span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Assumptions/2025-01-28 21-29-23.md" data-href="Research/Assumptions/2025-01-28 21-29-23.md" href="Research/Assumptions/2025-01-28 21-29-23.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 21-29-23</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>The pain from all types of <a data-href="Osteoarthritis" href="Osteoarthritis" class="internal-link" target="_blank" rel="noopener nofollow">Osteoarthritis</a> is equally sensitive to treatment by <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a></span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Assumptions/2025-01-28 21-20-02.md" data-href="Research/Assumptions/2025-01-28 21-20-02.md" href="Research/Assumptions/2025-01-28 21-20-02.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 21-20-02</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>The effect of <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> on <a data-href="Intervertebral Disc (IVD)" href="Intervertebral Disc (IVD)" class="internal-link" target="_blank" rel="noopener nofollow">Intervertebral Disc (IVD)</a> degeneration in response to IVD puncture is the same for rats of all ages</span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Assumptions/2025-01-28 21-08-35.md" data-href="Research/Assumptions/2025-01-28 21-08-35.md" href="Research/Assumptions/2025-01-28 21-08-35.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 21-08-35</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span><a data-href="Sinovitis" href="Sinovitis" class="internal-link" target="_blank" rel="noopener nofollow">Sinovitis</a> in all tissues is equally sensitive to treatment by <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a></span></td></tr><tr><td><span><a data-tooltip-position="top" aria-label="Research/Assumptions/2025-01-28 21-05-34.md" data-href="Research/Assumptions/2025-01-28 21-05-34.md" href="Research/Assumptions/2025-01-28 21-05-34.md" class="internal-link" target="_blank" rel="noopener nofollow" fileclass-name="Research Links">2025-01-28 21-05-34</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td><td><span>Intraperitoneal injection of <a data-href="Urolithin A" href="Urolithin A" class="internal-link" target="_blank" rel="noopener nofollow">Urolithin A</a> in mice will result in higher bioavailability than an equivalent dose taken by mouth in humans</span></td></tr></tbody></table></div>

